ReviewInternational journal of molecular sciences2011
The important molecular markers on chromosome 17 and their clinical impact in breast cancer.
Review in International journal of molecular sciences, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 40 citations in OpenAlex.
- A functional landscape for chromosome 17q in neuroblastoma: balancing replication stress and genomic stability.British journal of cancer · 2026Review
- Single-Sample Networks Reveal Intra-Cytoband Co-Expression Hotspots in Breast Cancer Subtypes.International journal of molecular sciences · 2024Article
- High prevalence of chromosome 17 in breast cancer micronuclei: a means to get rid of tumor suppressors?Human cell · 2024Article
- Comprehensive breast cancer risk analysis with whole exome sequencing and the prevalence ofBiomedical reports · 2024Article
- Mutagenic primer-based novel multiplex PCR-RFLP technique to genotype BECN1 SNPs rs10512488 and rs11552192.Molecular biology reports · 2024Article
- Effects of Human Papilloma Virus E6/E7 Oncoproteins on Genomic Structure in Head and Neck Squamous Cell Carcinoma.Cancers · 2022Article
- ZBTB7A, a miR-144-3p targeted gene, accelerates bladder cancer progression via downregulating HIC1 expression.Cancer cell international · 2022Article
- Promoter Hypermethylation and Expression Changes of BRCA1 Gene in a Cohort of Sporadic Breast Cancer Cases among Pakistani Population.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- ZNF750 represses breast cancer invasion via epigenetic control of prometastatic genes.Oncogene · 2020Article
- Proteogenomic Analysis of Protein Sequence Alterations in Breast Cancer Cells.Scientific reports · 2019Article
- Genetics and Epigenetics of Gastroenteropancreatic Neuroendocrine Neoplasms.Endocrine reviews · 2019Review
- Cross-Database Analysis Reveals Sensitive Biomarkers for Combined Therapy for ERBB2+ Gastric Cancer.Frontiers in pharmacology · 2018Article
- Visual Omics Explorer (VOE): a cross-platform portal for interactive data visualization.Bioinformatics (Oxford, England) · 2016Article
- Methylation of tumor suppressor genes is related with copy number aberrations in breast cancer.American journal of cancer research · 2015Article
- Article
- FISH analysis of PTEN in endometrial carcinoma. Comparison with SNP arrays and MLPA.Histopathology · 2014Article
- Evaluation of chromosome 17 polysomy in breast cancer by FISH analysis of whole nuclei, and its clinicopathological significance.Oncology letters · 2014Article
- Small activating RNA restores the activity of the tumor suppressor HIC-1 on breast cancer.PloS one · 2014Article
- Impact of polysomy 17 on HER2 testing of invasive breast cancer patients.International journal of clinical and experimental pathology · 2014Article
- An RNA-seq-based gene expression profiling of radiation-induced tumorigenic mammary epithelial cells.Genomics, proteomics & bioinformatics · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Abnormalities of chromosome 17 are important molecular genetic events in human breast cancers. Several famous oncogenes (HER2, TOP2A and TAU), tumor suppressor genes (p53, BRCA1 and HIC-1) or DNA double-strand break repair gene (RDM1) are located on chromosome 17. We searched the literature on HER2, TOP2A, TAU, RDM1, p53, BRCA1 and HIC-1 on the Pubmed database. The association of genes with chromosome 17, biological functions and potential significance are reviewed. In breast cancer, the polysomy 17 (three or more) is the predominant numerical aberration. HER2 amplification is widely utilized as molecular markers for trastuzumab target treatment. Amplified TOP2A, TAU and RDM1 genes are related to a significant response to anthracycline-based chemotherapy, taxane or cisplatin, respectively. In contrast, p53, BRCA1 and HIC-1 are important tumor suppressor genes related to breast carcinogenesis. This review focused on several crucial molecular markers residing on chromosome 17. The authors consider the somatic aberrations of chromosome 17 and associated genes in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.